SCHEMBL4418341

SCHEMBL4418341

CCOC(=O)COc1ccc(OCc2ccccc2)c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.59
CASP7 P55210 1/20 0.59
CASP9 P55211 1/20 0.59
ABCB1 P08183 1/20 0.55
KDM4E B2RXH2 5/20 0.55
MAPK1 P28482 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.50
CCR8 P51685 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 3/20 0.48
MAPT P10636 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MITF O75030 1/20 0.48
HSP90AA1 P07900 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7914606 0.84 NPC1 (0.56) CASP3CASP7CASP9ABCB1KDM4E
SCHEMBL13215072 0.83 KDM4E (0.52) CASP3CASP7CASP9ABCB1KDM4E
SCHEMBL4422051 0.82 CASP3 (0.61) CASP3CASP7CASP9ABCB1KDM4E
SCHEMBL6131789 0.82 KDM4E (0.60) ABCB1KDM4EMAPK1SMN1; SMN2LMNA
SCHEMBL27252709 0.81 ABCB1 (0.54) CASP3CASP7CASP9ABCB1KDM4E
SCHEMBL6187602 0.81 NR1H4 (0.64) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL6813530 0.80 APP (0.52) CASP3CASP7CASP9ABCB1KDM4E
SCHEMBL658806 0.80 KDM4E (0.54) CASP3CASP7CASP9ABCB1KDM4E
SCHEMBL10607164 0.80 HTR1A (0.58) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL9811660 0.79 HPGD (0.57) KDM4ESMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495001-B2 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
EP-1682507-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
WO-2005049572-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 WO disclosed
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG CASP3 718/4885CASP7 1348/4885CASP9 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.